Literature DB >> 23542873

The HLA Class II Associations with Rheumatic Heart Disease in South Indian Patients: A Preliminary Study.

Divya Bajoria1, Thangam Menon.   

Abstract

INTRODUCTION: Rheumatic heart disease (RHD) occurs in 30-45% of the patients with rheumatic fever (RF) and it leads to chronic valvular lesions. The human leukocyte antigen (HLA) might confer a susceptibility to RHD. The aim of the present study was to determine the prevalent HLA class II DR/DQ allelic types which were associated with rheumatic heart disease (RHD) in a small group of south Indian patients and to compare them with those in the control subjects.
METHODS: A total of 23 patients who were diagnosed with RHD and 6 control samples were included in this study. A low resolution HLA Class II DR/DQ typing was performed on the blood samples by the PCR-SSP method. RESULTS AND
CONCLUSION: The DRB3*01:01:02:01 allele showed a positive association with RHD, whereas the DQB1 loci alleles did not show any significant association.

Entities:  

Keywords:  HLA Class II DR/DQ typing; Rheumatic Heart Disease; South India

Year:  2013        PMID: 23542873      PMCID: PMC3592297          DOI: 10.7860/JCDR/2013/4509.2752

Source DB:  PubMed          Journal:  J Clin Diagn Res        ISSN: 0973-709X


  11 in total

1.  HLA antigen pattern of Kashmiri patients with rheumatic heart disease.

Authors:  M S Bhat; B A Wani; P A Koul; S D Bisati; M A Khan; S U Shah
Journal:  Indian J Med Res       Date:  1997-06       Impact factor: 2.375

Review 2.  Pathogenesis of group A streptococcal infections and their sequelae.

Authors:  Madeleine W Cunningham
Journal:  Adv Exp Med Biol       Date:  2008       Impact factor: 2.622

3.  HLA class II associations with rheumatic heart disease are more evident and consistent among clinically homogeneous patients.

Authors:  Y Guédez; A Kotby; M El-Demellawy; A Galal; G Thomson; S Zaher; S Kassem; M Kotb
Journal:  Circulation       Date:  1999-06-01       Impact factor: 29.690

4.  HLA class I and class II HLA DRB profiles in Egyptian children with rheumatic valvular disease.

Authors:  Nashwa El-Hagrassy; Farha El-Chennawi; Maysaa El-Sayed Zaki; Hossam Fawzy; Adel Zaki; Nabeil Joseph
Journal:  Pediatr Cardiol       Date:  2010-02-10       Impact factor: 1.655

Review 5.  Rheumatic fever in children.

Authors:  G DiSciascio; A Taranta
Journal:  Am Heart J       Date:  1980-05       Impact factor: 4.749

6.  Study of HLA-A, B, C, DR, DQ profile of patients with established rheumatic heart disease in Kashmir.

Authors:  B A Wani
Journal:  Indian Heart J       Date:  1997 Mar-Apr

7.  Immunologic and immunogenetic studies in rheumatic fever and rheumatic heart disease.

Authors:  K S Reddy; J Narula; R Bhatia; K Shailendri; M Koicha; V Taneja; B Jhingan; R B Pothineni; A N Malaviya; N K Mehra
Journal:  Indian J Pediatr       Date:  1990 Sep-Oct       Impact factor: 1.967

Review 8.  Rheumatic heart disease: mediation by complex immune events.

Authors:  L Guilherme; K F Köhler; J Kalil
Journal:  Adv Clin Chem       Date:  2011       Impact factor: 5.394

9.  Human leukocyte antigen (HLA) class II association with rheumatic heart disease in Pakistan.

Authors:  Sadia Rehman; Naveed Akhtar; Waqar Ahmad; Qasim Ayub; Syed Q Mehdi; Aisha Mohyuddin
Journal:  J Heart Valve Dis       Date:  2007-05

Review 10.  Some of the people, some of the time: susceptibility to acute rheumatic fever.

Authors:  Penelope A Bryant; Roy Robins-Browne; Jonathan R Carapetis; Nigel Curtis
Journal:  Circulation       Date:  2009-02-10       Impact factor: 29.690

View more
  2 in total

1.  A case of rheumatic valvular heart disease and autoimmune gastritis.

Authors:  Cátia Costa; David Durão; Marisa Peres; Margarida Leal
Journal:  BMJ Case Rep       Date:  2014-12-22

2.  Rheumatic heart disease in Uganda: the association between MHC class II HLA DR alleles and disease: a case control study.

Authors:  Emmy Okello; Andrea Beaton; Charles K Mondo; Paul Kruszka; Noah Kiwanuka; Richard Odoi-Adome; Juergen Freers
Journal:  BMC Cardiovasc Disord       Date:  2014-02-28       Impact factor: 2.298

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.